Core Technology and Methodology

The foundation of Anumanaâ??s offerings is the application of sophisticated neural networks to raw digital ECG data. While traditional ECG interpretation focuses on visible wave patterns (P, QRS, and T waves) to identify rhythm abnormalities like atrial fibrillation, Anumanaâ??s algorithms analyze subtle features of the electrical signal that are imperceptible to the human eye.

The company utilizes the Mayo Clinicâ??s extensive repository of millions of ECGs linked to clinical outcomes and electronic health records (EHR). By training models on this data, Anumana can identify the "electrical signature" of structural heart diseases and hemodynamic changes that typically require more expensive or invasive testing, such as echocardiography or cardiac catheterization.

Products and Clinical Solutions

1. ECG-AI LEF (Low Ejection Fraction)

The flagship product of Anumana is the ECG-AI LEF algorithm. In 2023, this tool received FDA 510(k) clearance as a medical device. It is designed to detect Low Ejection Fraction (LEF)â??a primary indicator of heart failureâ??using only a standard 12-lead ECG. * Functionality: The algorithm analyzes the ECG and provides a probability score indicating whether the patient has an ejection fraction of 40% or less. * Clinical Utility: Heart failure is often diagnosed late after symptoms appear. ECG-AI LEF allows clinicians to screen patients during routine office visits, identifying asymptomatic left ventricular dysfunction much earlier than standard protocols.

2. Pulmonary Hypertension (PH) AI

Anumana has developed a specialized algorithm to identify Pulmonary Hypertension, a condition characterized by high blood pressure in the arteries of the lungs. PH is notoriously difficult to diagnose, often taking years for a patient to receive an accurate assessment. * Development: This tool was developed in collaboration with Janssen Research & Development (part of Johnson & Johnson). * Mechanism: The AI identifies specific electrical patterns associated with right ventricular strain and pressure overload, which are early indicators of PH. * Impact: By flagging high-risk patients via a simple ECG, the tool facilitates earlier referral to specialists for confirmatory right-heart catheterization.

3. Hypertrophic Cardiomyopathy (HCM) Detection

Hypertrophic Cardiomyopathy is a leading cause of sudden cardiac death in young people and athletes. Anumana's HCM algorithm is designed to recognize the underlying electrical signals of a thickened heart muscle. * Targeting Unmet Needs: HCM is frequently misdiagnosed or missed entirely because the heart may appear normal during physical exams. * Integration: Like other Anumana tools, this is intended to function within the existing clinical workflow, providing an automated "second opinion" during routine cardiac screening.

4. Amyloidosis and Valvular Disease Screening

Anumana is actively expanding its pipeline to include detection for: * Cardiac Amyloidosis: A "masquerading" disease where protein deposits stiffen the heart. * Valvular Heart Disease: Identifying signatures of aortic stenosis and mitral regurgitation through electrical signals.

The Anumana ECG-AI Platform

Beyond individual algorithms, Anumana provides a cloud-based platform designed to integrate seamlessly into hospital systems and Electronic Health Records (EHR) like Epic or Cerner. * Interoperability: The platform can ingest ECG data from various hardware manufacturers (e.g., GE HealthCare, Philips). * Real-time Analysis: Once an ECG is uploaded to the hospital's database, the Anumana platform processes the data and returns a results report to the physician within seconds. * Research and Development Services: Anumana partners with pharmaceutical companies to use its AI tools as "digital companion diagnostics." This helps in clinical trials to identify appropriate patient cohorts and monitor drug efficacy or cardiotoxicity.

Strategic Acquisitions and Expansion

In 2022, Anumana acquired NeuTrace, a company specializing in electrophysiology (EP) data integration. This acquisition allowed Anumana to move into the EP lab, where it applies AI to intracardiac signals. This expansion enables the company to assist in more complex procedures like cardiac ablation and the management of complex arrhythmias, moving beyond non-invasive screening into procedural guidance.

Market Position and Impact

As a MedTech entity, Anumana stands out by moving away from traditional wearable gadgets toward clinical-grade, provider-focused software. By enhancing the utility of the 12-lead ECGâ??the most widely performed cardiac test in the worldâ??Anumana democratizes access to advanced cardiac diagnostics. Their approach reduces the "diagnostic odyssey" for patients with rare or complex heart conditions and optimizes the use of healthcare resources by ensuring that expensive imaging is directed toward the patients most likely to benefit from it.